Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02941926 · ClinicalTrials.gov registry record · Phase 3
Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC
A Phase 3 study of Breast Cancer, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 3,246
- Enrollment target
- 20
- Study locations
NCT02941926 is a Phase 3 study of Breast Cancer that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 3,246 participants, above the 2,801-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (16% higher). The trial reports 20 study locations across 7 states.
The verdict
NCT02941926, a Phase 3 study of Breast Cancer, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 3,246 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to collect additional safety and efficacy data for the combination of ribociclib + letrozole in men and pre/postmenopausal women with HR+HER2- advanced breast cancer and no prior hormonal treatment for advanced disease..
Conditions Studied
Interventions
- DRUG Letrozole
- DRUG Goserelin
- DRUG Ribociclib
- DRUG Leuprolide
Study Locations (20)
California
- Beverly Hills Cancer Center - Beverly Hills
- Pacific Shores Medical Group SC - Long Beach
- USC Norris Cancer Center - Los Angeles
- University of California Irvine UC Irvine (11) - Orange
- Ventura County Hematology and Oncology - Oxnard
- PCR Oncology - Pismo Beach
- California Pacific Medical Center Onc Dept - San Francisco
Florida
- Florida Cancer Research Institute Dept of Oncology - Davie
- Foundation for Sickle Cell Disease Research - Hollywood
- Watson Clinic Center for Research 1730 Location - Lakeland
- Mid Florida Hematology and Onc Ctr - Orange
Arizona
- Ironwood Cancer and Research Centers - Chandler
- Arizona Oncology Associates - Phoenix
- Arizona Oncology Associates Arizona Oncology Assoc. (2) - Tucson
Colorado
- Centura Health Research Center Centura Health Research Center - Denver
- Poudre Valley Hospital Poudre Valley Health System - Fort Collins
- Valley View Hospital Cancer Center - Glenwood Springs
Alaska
- Alaska Cancer Research and Education Center - Anchorage
Arkansas
- Highlands Oncology Group - Fayetteville
Georgia
- Summit Cancer Care Summit Cancer Care (SC) - Savannah
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,246 participants |
| Start Date | 2016-11-30 |
| Est. Completion | 2022-11-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02941926
The ClinicalTrials.gov registry entry for NCT02941926 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 3,246 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 2,801-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (16% higher). The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 4 interventions - of which Letrozole is the first listed.
NCT02941926 reports 20 study locations spanning 7 distinct geographic areas - top geographies include California, Florida, Arizona.
Frequently Asked Questions
What is clinical trial NCT02941926 about?
NCT02941926 is a clinical study titled "Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC". The purpose of this study is to collect additional safety and efficacy data for the combination of ribociclib + letrozole in men and pre/postmenopausal women with HR+HER2- advanced breast cancer and no prior hormonal treatment for advanced disease..
What is the current status of trial NCT02941926?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 3,246 participants. The study started on 2016-11-30. Estimated completion is 2022-11-09.
What conditions does trial NCT02941926 study?
This clinical trial studies the following conditions: Breast Cancer.
What interventions are being tested in trial NCT02941926?
The interventions under investigation include: Letrozole (DRUG), Goserelin (DRUG), Ribociclib (DRUG), Leuprolide (DRUG).
Who is sponsoring clinical trial NCT02941926?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02941926 being conducted?
This trial has 20 study locations across Alaska, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
RECRUITING · Phase 3
-
Intensity Modulated Radiotherapy (IMRT) vs. 3D-conformal Accelerated Partial Breast Irradiation (APBI) for Early Stage Breast Cancer After Lumpectomy
RECRUITING · Phase 3
-
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer
RECRUITING · Phase 3
-
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
RECRUITING · Phase 3
-
A Study of a Comprehensive Prevention Program to Reduce Lymphedema After Axillary Lymph Node Dissection in People With Breast Cancer
RECRUITING · Phase 3
-
Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.